NYSE$TMO

Thermo Fisher Scientific Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Thermo Fisher's Q3 2020 earnings significantly increased due to strong revenue growth and pandemic response.

Thermo Fisher Scientific reported a strong third quarter in 2020, with revenue increasing by 36% to $8.52 billion and adjusted EPS increasing by 91% to $5.63. The company benefited from $2.0 billion in COVID-19 related revenue and growth in its base business.

  • Revenue increased 36% to $8.52 billion.
  • GAAP diluted EPS increased 157% to $4.84.
  • Adjusted EPS increased 91% to $5.63.
  • Generated $2.0 billion of COVID-19 related revenue and returned the base business to growth.

Headline financials

Total Revenue

$8.52B

Previous: $6.27B+35.9%
EPS (adj)

$5.63

Previous: $2.94+91.5%
Adjusted Operating Margin

32.9%

Previous: 22.7%+44.9%
GAAP Operating Margin

28.5%

Previous: 15.1%+88.7%
Capital Expenditures

-$888M

Previous: -$637M-39.4%
Free Cash Flow

$1.05B

Previous: $123M+749.6%
Net Income

$1.93B

Previous: $760M+154.3%
Operating Income

$2.43B

Previous: $946M+156.4%
Gross Profit

$4.46B

Previous: $2.89B+54.3%
Cash & Equivalents

$7.54B

Previous: $1.27B+492.3%
Total Assets

$64.1B

Previous: $56.7B+12.9%
Stock-Based Comp

$52M

Previous: $42M+23.8%

Revenue & EPS history

Thermo Fisher · Revenue · Quarterly

$8.52B

Q3 2020+35.9%vs Q3 2019
Beat estimate in 16 of 16 quarters(100%)
ActualEstimate

Revenue by segment

Thermo Fisher · $9.3B total across 4 segments · Q3 2020

  • Life Sciences Solutions
    $3.42B+101.3%
  • Lab Products & Biopharma
    $3.11B+18.8%
  • Specialty Diagnostics
    $1.43B+62.7%
  • Analytical Instruments
    $1.34B-1.6%

Forward guidance

Thermo Fisher is on track to deliver a record year and is positioning the company for an even brighter future.

Tailwinds

  • Launching new products across the company.
  • Scaling up production of sample collection products.
  • Scaling up production of essential laboratory supplies.
  • Increasing pharma services capacity to support new therapies and vaccines.
  • Creating a strong foundation for future growth.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+0.5%

Avg return

Earnings day

+0.4%

Avg return

5 days after

-0.1%

Avg return

30 days after

53%

39 / 73 earnings

Positive

+9.9%

Q2 2012

Best reaction

-7.8%

Q2 2011

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.6%-8.5%-12.7%
Q4 2025-4.6%-6.2%-14.3%
Q3 2025+1.5%+1.0%+5.3%
Q2 2025+3.2%+5.8%+6.3%
Q1 2025-0.7%-3.1%-9.4%
Q4 2024+6.8%+2.2%-6.9%
Q3 2024-4.9%-5.8%-12.5%
Q2 2024+7.7%+9.4%+9.8%
Q1 2024-0.5%+0.4%+1.6%
Q4 2023-2.6%-2.7%+1.6%
Q3 2023-3.9%-5.3%+7.1%
Q2 2023-1.9%-3.9%-5.1%
Q1 2023-1.0%+0.0%-4.8%
Q4 2022+2.9%+1.0%-1.9%
Q3 2022-3.2%-0.1%+7.1%
Q2 2022+2.8%+0.7%-3.1%
Q1 2022+6.2%+5.0%+10.0%
Q4 2021+0.1%-1.2%-7.9%
Q3 2021+1.9%+4.4%+5.0%
Q2 2021+0.7%+0.6%+3.4%
Q1 2021-3.2%-4.2%-3.4%
Q4 2020+1.7%-3.4%-11.5%
Q3 2020+3.6%+3.7%-3.1%
Q2 2020+1.8%+2.6%+6.3%
Q1 2020+0.3%+7.2%+6.5%
Q4 2019-6.2%-2.4%-12.9%
Q3 2019+4.4%+6.7%+9.5%
Q2 2019-1.0%-1.6%-8.3%
Q1 2019+2.1%+3.3%+3.0%
Q4 2018+3.7%+2.8%+11.5%
Q3 2018+3.1%+2.2%+5.2%
Q2 2018+5.7%+4.2%+6.0%
Q1 2018+0.3%-1.3%+0.2%
Q4 2017+3.6%-2.9%-3.8%
Q3 2017+3.1%-1.2%-0.4%
Q2 2017-2.7%-2.6%-1.6%
Q1 2017+5.0%+4.9%+9.2%
Q4 2016+6.7%+5.7%+11.1%
Q3 2016-0.6%-1.4%-2.6%
Q2 2016-0.0%-1.5%-4.1%
Q1 2016-2.0%
Q4 2015-2.8%
Q3 2015-3.6%
Q2 2015+3.0%
Q1 2015-3.6%
Q4 2014+0.7%
Q3 2014-1.7%
Q2 2014+2.0%
Q1 2014-4.1%
Q4 2013+3.0%
Q3 2013+1.3%
Q2 2013+1.9%
Q1 2013-0.6%
Q4 2012+6.2%
Q3 2012+7.1%
Q2 2012+9.9%
Q1 2012+4.1%
Q4 2011-0.1%
Q4 2010-0.1%
Q3 2011-1.5%
Q2 2011-7.8%
Q1 2011-0.2%
Q3 2010-1.7%
Q2 2010+1.0%
Q1 2009-6.2%
Q1 2010+0.2%
Q4 2007-1.3%
Q4 2009-1.3%
Q3 2008-2.8%
Q3 2009-2.8%
Q2 2008+0.5%
Q2 2009+0.5%
Q4 2008+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro